Samuele Cazzamalli
Overview
Explore the profile of Samuele Cazzamalli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
492
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Bocci M, Zana A, Principi L, Lucaroni L, Prati L, Gilardoni E, et al.
J Control Release
. 2024 Feb;
367:779-790.
PMID: 38346501
Small molecule-drug conjugates (SMDCs) are increasingly considered as a therapeutic alternative to antibody-drug conjugates (ADCs) for cancer therapy. OncoFAP is an ultra-high affinity ligand of Fibroblast Activation Protein (FAP), a...
12.
Bisbal Lopez L, Ravazza D, Bocci M, Zana A, Principi L, Dakhel Plaza S, et al.
Front Pharmacol
. 2023 Dec;
14:1320524.
PMID: 38125888
Immune-stimulating antibody conjugates (ISACs) equipped with imidazoquinoline (IMD) payloads can stimulate endogenous immune cells to kill cancer cells, ultimately inducing long-lasting anticancer effects. A novel ISAC was designed, featuring the...
13.
Puglioli S, Oehler S, Prati L, Scheuermann J, Bassi G, Cazzamalli S, et al.
Chem Sci
. 2023 Nov;
14(43):12026-12033.
PMID: 37969600
DNA-encoded chemical libraries (DELs) are powerful drug discovery tools, enabling the parallel screening of millions of DNA-barcoded compounds. We investigated how the DEL input affects the hit discovery rate in...
14.
Tumor-Targeted Interleukin 2 Boosts the Anticancer Activity of FAP-Directed Radioligand Therapeutics
Galbiati A, Dorten P, Gilardoni E, Gierse F, Bocci M, Zana A, et al.
J Nucl Med
. 2023 Sep;
64(12):1934-1940.
PMID: 37734838
We studied the antitumor efficacy of a combination of Lu-labeled radioligand therapeutics targeting the fibroblast activation protein (FAP) (OncoFAP and BiOncoFAP) with the antibody-cytokine fusion protein L19-interleukin 2 (L19-IL2) providing...
15.
Torng W, Biancofiore I, Oehler S, Xu J, Xu J, Watson I, et al.
ACS Omega
. 2023 Jul;
8(28):25090-25100.
PMID: 37483198
DNA-Encoded Chemical Libraries (DELs) have emerged as efficient and cost-effective ligand discovery tools, which enable the generation of protein-ligand interaction data of unprecedented size. In this article, we present an...
16.
Oehler S, Lucaroni L, Migliorini F, Elsayed A, Prati L, Puglioli S, et al.
Nat Chem
. 2023 Jul;
15(10):1431-1443.
PMID: 37400597
DNA-encoded chemical libraries (DELs) consist of large chemical compound collections individually linked to DNA barcodes, facilitating pooled construction and screening. However, screening campaigns often fail if the molecular arrangement of...
17.
Zana A, Puig-Moreno C, Bocci M, Gilardoni E, Di Nitto C, Principi L, et al.
Bioconjug Chem
. 2023 Jul;
34(7):1205-1211.
PMID: 37399501
We present the first comparative evaluation of chemically defined antibody-drug conjugates (ADCs), small molecule-drug conjugates (SMDCs), and peptide-drug conjugates (PDCs) targeting and activated by fibroblast activation protein (FAP) in solid...
18.
Bassi G, Cazzamalli S, Oehler S, Lucaroni L, Georgiev T, Favalli N, et al.
Eur J Nucl Med Mol Imaging
. 2023 Jun;
50(10):2947-2949.
PMID: 37341746
No abstract available.
19.
Zana A, Galbiati A, Gilardoni E, Bocci M, Millul J, Sturm T, et al.
Clin Cancer Res
. 2022 Oct;
28(24):5440-5454.
PMID: 36215129
Purpose: Small molecule drug conjugates (SMDC) are modular anticancer prodrugs that include a tumor-targeting small organic ligand, a cleavable linker, and a potent cytotoxic agent. Most of the SMDC products...
20.
Lucaroni L, Georgiev T, Prodi E, Puglioli S, Pellegrino C, Favalli N, et al.
Eur J Nucl Med Mol Imaging
. 2022 Oct;
50(3):957-961.
PMID: 36184692
Purpose: Recently, Pluvicto™ ([Lu]Lu-PSMA-617), a small-molecule prostate-specific membrane antigen (PSMA) radioligand therapeutic, has been approved by the FDA in metastatic castration-resistant prostate cancer. Pluvicto™ and other PSMA-targeting radioligand therapeutics (RLTs)...